

INDEX

- Anti-vaccination activists and groups, 66–67
- AstraZeneca, 47, 49–50, 62
- At-risk manufacturing, 46–50
- Autumn and Winter Plan, 26–27
- Bill and Melinda Gates Foundation, 46–47
- BMJ*, 29–30, 90–91
- Cabinet Office Briefing Rooms (COBRA), 14–15
- Care home managers, 69–70
- Conditional marketing authorisation (CMA), 52
- Containment, 14–15
- Coronavirus Act 2020, 9–10, 26–27
- Coronavirus Job Retention Scheme, 16–17, 21, 27
- Countervailing powers theory, 5
- COVID-19
 - alert system, 18
 - challenges and demands, 14
 - in England, 1
 - freedom day and individual responsibility, 23–27
 - non-pharmaceutical interventions, 82–84
 - non-pharmaceutical policy response to, 13–14
 - pandemic, 2, 10
 - responding to first wave, 14–18
 - response to second wave, 18–23
 - shape of and influences on non-pharmaceutical policy response, 27–38
 - situating and tracing origins and onset of, 2–4
 - social inequalities in vaccine take-up, 82, 85, 88
 - sociological analysis, 1–2
 - vaccines, 43–45, 48, 66
- COVID-19 Vaccines Global Access (COVAX), 59–61
- Delay, 14–15
- Delta variant, 23–24
- Department of Health and Social Care (DHSC), 13–14
- Distributive justice, 54–55
- ‘Eat Out to Help Out’ scheme, 21
- Emergency legal powers, 16–17
- European Medicines Agency (EMA), 51–52
- European Union (EU), 76–77
- Excess mortality, 74–75
- Exercise Cygnus* (2016), 13–14
- Framing, 7–8
- Freedom Day, 23, 27, 57
- Government’s policy approach, characterising, 27–29
- ‘Grab a job’ campaign, 63–64
- Health and Social Care Act (2012), 32–33
- Healthcare sphere, 4–5
- Hepatitis B vaccine, 69
- Herd immunity, 15–16, 28–29

- Hospital Accident and Emergency services (A&E services), 14
- Hospital hubs, 63–64
- Individual responsibility, 23–27
- Infectious diseases, 1
- Influenza, 2
- Infodemic, 7–8
- International Coalition of Medicines Regulatory Authorities, 53
- International provision, 59–63
- Investment, 45–46
- Joint Committee on Vaccination and Immunisation (JCVI), 42–43, 55, 91
evidence consulted by, 56–57
recommendations, 56
- Lab leak theory, 3
Lancet, The, 3, 24, 29–30, 90–91
Long COVID, 78
- Mandatory vaccination, 67–70
- Marginalisation of public health, 32–33
- Marketing Authorisation, 51–52
- Media, role and influence of, 34–36
- Medical profession, 29–32
- Medical scientific expertise, 29–32
- Medicines and Healthcare products Regulatory Agency (MHRA), 43, 51–52, 57–58, 92–93
- Mental health, 79
- Middle East respiratory syndrome (MERS), 2
- Mitigation, 14–15
- Moderna vaccine, 51–52
- National Booking Service, 63–64
- National Institute for Health Protection, 20
- News media journalists, 94
- NHS, 6, 14–16
COVID Pass, 67
- COVID-19 app, 25–26
- leaders, 21–22
- patients, 17
- providers, 17–18
- Test and Trace system, 19–20, 26–27, 63–64
- Non-pharmaceutical interventions, 82–84
- Non-pharmaceutical policy response, shape of and influences on, 27–38
- Office for National Statistics (ONS), 21–22
- Oxford-AstraZenca vaccine, 43–46, 48–52
- Oxford-AstraZeneca vaccine, 85–86
- Parallel epidemic, 81–82
- Patient trust, 8
- Personal Protective Equipment (PPE), 13–14, 18, 79–80
- Pfizer/BioNTech COVID-19 vaccine, 44–45, 51–52
- Pharmacovigilance, 43
- Phase I trials, 50–51
- Phase II trials, 50–51
- Phase III trials, 50–51
- Pingdemic, 25–26
- Plague, 2
- Policies assessment, 73
agenda for research, 96–98
COVID-19 and social inequalities, 82–88
impact on public health, 73–82
power, policy and COVID-19 pandemic, 88–95
- Polymerase chain reaction (PCR), 33–34
- Post-COVID-19 syndrome. *See* Long COVID
- Prioritisation, 54–63
- Private sector, 33–34
- Public and trust, 36–38
- Public health

- impact on, 73–82
- marginalisation, 32–33
- services, 6
- Public Health Emergency of International Concern (PHEIC), 3–4
- Public Health England (PHE), 20
- Public trust, 8, 94–95
- Publicly funded research, 46–50
- Randomised controlled trials (RCTs), 50–51
- RNA vaccines, 43, 46
- Rule of six, 22
- Safe and effective vaccines, 50–54
- SARS-CoV-2, 2–3
- Scientific Advisory Group for Emergencies (SAGE), 14–15, 90–91
- Severe acute respiratory syndrome (SARS), 2
- Smallpox, 2
- Social care, 79–81
- Social Care Working group of SAGE, 69–70
- Social distancing rule, 19
- Social inequalities in vaccine take-up, 82, 85, 88
- Social media, 7–8, 66–67
- Suppression policy, 15–16
- Systematic testing, 17
- Tier system, 22
- Traditional media, 7–8, 93–94
- Transparency, 54, 96–97
- Trust, 8
- UK Health Security Agency (UKHSA), 32–33
- Universal Credit, 16–17
- Vaccination programme, 41–42
 - designing and delivering, 42–43
 - places, staff and public, 63–70
 - prioritisation, 54–63
 - supply, manufacturing and regulation, 44–54
- Vaccine Taskforce (VTF), 42, 44–45
- Vaccines, 7
 - coverage, 8–9, 64, 67
 - hesitancy and rejection, 8–9
 - nationalism, 59–63
 - passports, 67–70
 - prioritisation strategy, 77
 - war, 62
- Vaccines Minister, 42–43
- Viral vector vaccines, 43
- Viruses, 46
- Wellcome Trust, 60–61
- West African Ebola outbreak, 2
- Working Tax Credit, 16–17
- World Health Organisation (WHO), 2–4, 18, 60–61
 - Ad Hoc Expert Group on Next Steps for COVID-19 Vaccine Evaluation, 53
- Yellow fever, 2